

Date Shipment Needed: \_\_\_\_\_ Ship To:  Patient  Prescriber

Nursing needed;  Training needed ► All the supplies including syringes and needles will be dispensed if needed.

**BIOSIMILAR RHEUMATOLOGY NON-IV REFERRAL FORM**

**PATIENT INFORMATION**

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Sex:  M  F  Other: \_\_\_\_\_ Weight: \_\_\_\_\_  lbs.  kg.

SSN: \_\_\_\_\_ Phone: \_\_\_\_\_ Allergies: \_\_\_\_\_

Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Emergency Contact: \_\_\_\_\_ Phone: \_\_\_\_\_  **Additional Information Attached**

**PRESCRIBER INFORMATION**

Prescriber: \_\_\_\_\_ NPI: \_\_\_\_\_ DEA: \_\_\_\_\_ State Lic: \_\_\_\_\_

Supervising Physician: \_\_\_\_\_ Practice Name: \_\_\_\_\_

Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Key Office Contact: \_\_\_\_\_ Phone: \_\_\_\_\_

**DIAGNOSIS INFORMATION / MEDICAL ASSESSMENT**

**Primary Diagnosis:**  M06.9 Rheumatoid Arthritis  L40.54; L40.59 Psoriatic Arthritis  M08.00 Unspecified Juvenile Rheumatoid Arthritis  M08.3 Juvenile Rheumatoid Polyarthritits (Seronegative)

M08.20 Juvenile Idiopathic Arthritis  M45.9 Ankylosing Spondylitis  M33.20 Polymyositis  M81.0 Osteoporosis  M15.0; M15.9 Osteoarthritis  Other: \_\_\_\_\_

• Has patient been treated *previously* for this condition?  Yes  No Is patient *currently* on therapy?  Yes  No Please list medication(s) and treatment duration: \_\_\_\_\_

• Will patient stop taking the above medication(s) before starting the new medication?  Yes  No If yes, how long should patient wait before starting the new medication? \_\_\_\_\_

• Other medications patient is currently taking including OTC medications with dosage and direction (or fax medication profile): \_\_\_\_\_

• Has patient received a **Quatiferon gold, Tspot or PPD (tuberculosis) Skin Test?**  Yes  No Date: \_\_\_\_\_ Results:  Negative  Positive  
*Prior to initiating treatment and periodically during therapy, patient should be evaluated for active tuberculosis and tested for latent infection*

**INSURANCE INFORMATION**

**Please attach front and back of patient's insurance card (medical and prescription)**

**COPAY CARD ENROLLMENT**

**Please check if enrolling in copay card** Copay ID: \_\_\_\_\_

**PRESCRIPTION INFORMATION**

<b>Abrilada®</b> <input type="checkbox"/> 40 mg/0.8 mL Pen OR <input type="checkbox"/> 40 mg/0.8 mL Syringe <input type="checkbox"/> 40 mg/0.8 mL Pen every week OR <input type="checkbox"/> 40 mg/0.8 mL Syringe every other week	QTY: _____   Refills: _____
<b>Amjevita®</b> <input type="checkbox"/> 40 mg/0.8 mL Pen OR <input type="checkbox"/> 40 mg/0.8 mL Syringe <input type="checkbox"/> 40 mg SQ every week <input type="checkbox"/> 40 mg SQ every other week	QTY: _____   Refills: _____
<b>Cyltezo®</b> <small>(Adalimumab-adbm)</small> <input type="checkbox"/> 40 mg/0.8 mL Pen OR <input type="checkbox"/> 40 mg/0.8 mL Syringe <input type="checkbox"/> 40 mg SQ every week <input type="checkbox"/> 40 mg SQ every other week	QTY: _____   Refills: _____
<b>Hadlima®</b> <input type="checkbox"/> 40 mg/0.4 mL Pen OR <input type="checkbox"/> 40 mg/0.4 mL Prefilled Syringe OR <input type="checkbox"/> 40 mg/0.8 mL Pen OR <input type="checkbox"/> 40 mg/0.8 mL Syringe <input type="checkbox"/> 40 mg SQ every week <input type="checkbox"/> 40 mg SQ every other week	QTY: _____   Refills: _____
<b>Hulio®</b> <small>(Adalimumab-figp)</small> <input type="checkbox"/> 40 mg/0.8 mL Pen OR <input type="checkbox"/> 40 mg/0.8 mL Syringe <input type="checkbox"/> 40 mg SQ every week <input type="checkbox"/> 40 mg SQ every other week	QTY: _____   Refills: _____
<b>Humira®</b> <input type="checkbox"/> 40 mg/0.4 mL Pen CF <input type="checkbox"/> 40 mg/0.4 mL Prefilled Syringe CF <input type="checkbox"/> 20 mg/0.4 mL Prefilled Syringe CF <input type="checkbox"/> 10 mg/0.2 mL Prefilled Syringe CF <input type="checkbox"/> 40 mg SQ every other week <input type="checkbox"/> 20 mg SQ every other week <input type="checkbox"/> 10 mg SQ every other week <input type="checkbox"/> 40 mg SQ every week <input type="checkbox"/> Alternate Dose: _____	<input type="checkbox"/> <b>Enroll in Humira Complete Program</b> QTY: _____   Refills: _____ QTY: _____   Refills: _____
<b>Hyrimoz®</b> <small>(Adalimumab-adaz)</small> <input type="checkbox"/> 40 mg/0.4 mL Pen OR <input type="checkbox"/> 40 mg/0.4 mL Syringe <input type="checkbox"/> 40 mg SQ every week <input type="checkbox"/> 40 mg SQ every other week	QTY: _____   Refills: _____
<b>Idacio®</b> <small>(Adalimumab-aacf)</small> <input type="checkbox"/> 40 mg/0.8 mL Pen OR <input type="checkbox"/> 40 mg/0.8 mL Syringe <input type="checkbox"/> 40 mg SQ every week <input type="checkbox"/> 40 mg SQ every other week	QTY: _____   Refills: _____
<b>Yusimry®</b> <input type="checkbox"/> 40 mg/0.8 mL Pen <input type="checkbox"/> 40 mg SQ every week <input type="checkbox"/> 40 mg SQ every other week	QTY: _____   Refills: _____
<b>Yuflyma®</b> <input type="checkbox"/> 40 mg/0.4 mL Pen OR <input type="checkbox"/> 40 mg/0.4 mL Syringe <input type="checkbox"/> 40 mg SQ every week <input type="checkbox"/> 40 mg SQ every other week	QTY: _____   Refills: _____
<input type="checkbox"/> <b>Other:</b> _____	QTY: _____   Refills: _____

**Prescriber's Signature:** \_\_\_\_\_  DAW (Dispense as Written) **Date:** \_\_\_\_\_

Prescriber certifies that this referral form contains an original signature and is signed by the treating prescriber. **NO STAMPED SIGNATURES WILL BE ACCEPTED.** Where required by law, send electronic prescription or on official state prescription blank. In the event requested agent is not available through AcariaHealth, this prescription shall be forwarded to an eligible pharmacy.

**IMPORTANT NOTICE:** This message may contain privileged and confidential information and is intended only for the individual named. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document by mistake, then destroy this document. Please direct all verification or notification to AcariaHealth or any of its subsidiaries using the contact information provided on this coversheet.